Multipotentiality of Luliconazole against Various Fungal Strains: Novel Topical Formulations and Patent Review

Abstract

Background: Luliconazole is a broad-spectrum antifungal agent with impactful fungicidal and fungistatic activity. It has shown exceptional potency against miscellaneous fungal strains like Candida, Aspergillus, Malassezia, Fusarium species and various dermatophytes. Objective: Luliconazole belongs to class Ⅱ of the Biopharmaceutical Classification System with low aqueous solubility. Although it is available conventionally as 1% w/v topical cream, it has limitations of lower skin permeation and shorter skin retention. Therefore, nanoformulations based on various polymers and nanostructure carriers can be employed to overcome the impediments regarding topical delivery and efficacy of luliconazole. Methods: In this review, we have tried to provide insight into the literature gathered from authentic web resources and research articles regarding recent research conducted on the subject of formulation development, patents, and future research requisites of luliconazole. Results: Nanoformulations can play a fundamental role in improving topical delivery by escalating dermal localization and skin penetration. Fabricating luliconazole into nanoformulations can overcome the drawbacks and can efficiently enhance its antimycotic activity. Conclusion: It has been concluded that luliconazole has exceptional potential in the treatment of various fungal infections, and therefore, it should be exploited to its maximum for its innovative application in the field of mycology.

Prevalence and Antifungal Susceptibility of Sporothrix species in Guangzhou, Southern China

“…However, the clinical limitation of lower skin penetration and shorter skin retention time was need to be considered. A recent study showed nanoparticles based on various polymers can be used to overcome barriers of topical delivery and efficacy of LULI 34 . LULI has great potential in the treatment of various fungal infections, while further studies are needed to confirm the therapeutic effect on sporotrichosis.…”